JPRN-UMIN000036861已完成未知
Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials - brigatinib veusus alectinib in NSCLC
Showa University School of Medicine, Department of Medicine, Division of Respiratory Medicine and Allergology,0 个研究点目标入组 785 人开始时间: 2019年5月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 785
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Studies of patients with double cancer, immunecompromised patients, patients of poor performance status, and patients previously treated with ALT-TKIs
研究者
相似试验
已完成
2 期
Barossa studyJPRN-jRCT2080224774Department of Thoracic Oncology, National Cancer Center Hospital East52
招募中
2 期
Phase II Study of Brigatinib for ALK-positive advanced non-small cell lung cancer with brain metastasesALK-positive advanced non-small cell lung cancer with brain metastasesnon-small cell lung cancerJPRN-jRCTs071230025aoki Katsuhiko22
招募中
不适用
Real-world outcomes of brigatinib compared to alectinib as a second-line therapy after crizotinib in advanced anaplastic lymphoma kinase positive non-small cell lung cancer patientsKCT0005952Asan Medical Center60
招募中
1 期
Scientific research on the safety and efficacy of the drug brigatinib in children and young adults with a tumour with an ALK positive deviatiorelapsed/refractory ALK rearranged** or ALK mutated tumors, including relapsed/refractory ALK+ALCL and ALK+IMT.EUCTR2021-002713-34-PLPrincess Maxima Center for Pediatric Oncology in The Netherlands65
招募中
2 期
A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumorsALK+ ALCL, IMT en andere ALK+ tumorenALK positive tumors10024324NL-OMON50304Prinses Máxima Centrum voor Kinderoncologie5